

August 8, 2025

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001

National Stock Exchange of India Limited
Exchange Plaza,
Bandra-Kurla Complex,
Bandra (East),
Mumbai - 400 051

Scrip code: 512529

Scrip code: SEQUENT

Subject: Intimation under Regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') – Proposed change in Management structure

Dear Sir/Madam,

Following the progress of regulatory processes for the proposed merger of Viyash Lifesciences with Sequent Scientific, including the receipt of NoC from stock exchanges and the directions from the NCLT Hyderabad, to hold NCLT convened meetings of the shareholders and creditors' on August 30, 2025 (a key step in the NCLT approval process), the Board of directors of Sequent at its meeting held today discussed the next steps and future plans for the combined business.

As a key first step to drive alignment within businesses, and in order to realise potential synergies in an accelerated manner, Sequent's Board has deliberated and proposed the leadership team for the combined business following the effectiveness of the proposed merger.

Subject and contingent to the effectiveness of the proposed merger, Dr.Hari Babu Bodepudi, Founder and Chief Executive Officer of Viyash and a Non-Executive Director of Sequent, will be appointed as the Managing Director and Group Chief Executive Officer of the combined entity.

Mr. Rajaram Narayanan, Sequent's current Managing Director and Chief Executive Officer, will transition to the role of Chief Executive Officer - Animal Health. He shall also continue as a Whole time Director on the Board of the combined entity.

The above proposals are contingent upon the effectiveness of the proposed merger, and will be made subject to obtaining all necessary statutory approvals including passing of all necessary resolutions in the said matters.

Profile of Dr. Hari Babu Bodepudi

Dr. Hari Babu Bodepudi holds a PhD degree in Organic Chemistry and has over 30 years of Industry experience permeating diverse roles in Research, Manufacturing, Quality and operations in both APIs and Oral Solids. During the last 20 years, he held several leadership roles in technical and commercial operations in Mylan Laboratories, including being the COO of Mylan India, CEO of Mylan India and the Global COO of Mylan. He was responsible for more than 50 Mylan facilities globally, managing more than 200 APIs and 15000 SKUs of different formulations. He has hands-on experience in global supply chain, regulatory, API R&D, quality and Commercial operations.

SeQuent Scientific Limited

Registered Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Hyderabad - 500033, Telangana

Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra

Tel No.: +91 9391139986 / 22-4111 4777 | **CIN:** L99999TS1985PLC196357

Website: <http://www.sequent.in> | **Email Id:** investorrelations@sequent.in

Profile of Mr. Rajaram Narayanan

Mr. Rajaram Narayanan has over 30 years of experience, during which he has held key leadership roles in global pharmaceutical and consumer product companies. Since joining SeQuent in April 2022 as Managing Director, he has led the strategic reshaping of the organization, returning it to profitability and growth. Prior to joining SeQuent, he was the Managing Director and Country Chair of the Sanofi in India for nearly 5 years. He began his career with Hindustan Unilever, after completing his education in Engineering and Business Management. At Unilever he held various commercial assignments of increasing responsibility during an 18 year career in India and Asian markets.

There is no inter-se relationship between Dr. Hari Babu Bodepudi, Mr. Rajaram Narayanan and other Directors on the Board.

The Board meeting started at 4.35 p.m. and concluded at 5.15 p.m.

Thanking you,

Yours faithfully,
For **Sequent Scientific Limited**

Yoshita Vora
Company Secretary & Compliance Officer

SeQuent Scientific Limited

Registered Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Hyderabad - 500033, Telangana

Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra

Tel No.: +91 9391139986 / 22-4111 4777 | **CIN:** L99999TS1985PLC196357

Website: <http://www.sequent.in> | **Email Id:** investorrelations@sequent.in